Skip to content
Back to Blog
Bio
2026-05-068 min read17

Pharma-Bio Venture 4UP Strategy: Leveraging the MOHW-MSS Whole-Lifecycle Collaboration Plan

An analysis of the four pillars and stage-specific gap-bridging measures of the MOHW-MSS '4UP Strategy' announced in March 2026, with practical use-case scenarios for SME bio companies.

KITIM Consulting Team

1. Overview of the 4UP Strategy (Announced March 24, 2026)

On March 24, 2026, the Ministry of Health and Welfare (MOHW) and the Ministry of SMEs and Startups (MSS) jointly announced the '4UP Strategy' to nurture pharma-bio ventures. The initiative aims to build an integrated government support system for creating K-blockbuster new drugs.

Four Pillars of the 4UP Framework

  • Scale-Up: Foster mid-sized bio companies with annual revenue exceeding KRW 10 billion, targeting 50 firms over 5 years
  • Speed-Up: Reduce commercialization timelines by 30% through intensive support during clinical trials and approval phases
  • Level-Up: Customized R&D support by Technology Readiness Level (TRL), with collaboration between KHIDI and SBC
  • Synergy-Up: Eliminate inter-ministry silos and build an integrated platform
  • As a new collaborative program between MOHW and MSS, an annual budget of approximately KRW 420 billion has been allocated, with the core objective of bridging stage-specific support gaps for K-blockbuster drug creation.

    2. Stage-Specific Gap-Bridging Strategies

    Startup/Early Stage: K-Startup·KHIDI Integrated Application System

    Previously, early-stage bio ventures had to apply separately to K-Startup (MSS) and KHIDI (MOHW) programs. Starting June 2026, an integrated application system will go live, allowing simultaneous submission to both ministries with shared evaluation materials.

  • Eligibility: Bio ventures within 3 years of founding (seed to pre-Series A)
  • Funding: Up to KRW 500 million per company (split across 2 years)
  • Accelerated review: Reduced from 4 months to 2 months
  • Growth Stage: AI-Driven Venture-Pharma Joint R&D

    A new program will match mid-sized pharmaceutical companies with AI-based bio ventures for joint R&D.

  • Matching scale: 30 consortia selected annually
  • Funding: Up to KRW 2 billion per consortium over 3 years
  • Focus areas: AI drug discovery, digital therapeutics, bio data analytics
  • Private matching: Pharmaceutical companies must match 50% or more
  • Globalization: 'K-Bio Tech Commercialization Running Together'

    An integrated package for global expansion, supporting technology transfer, overseas clinical trials, and local subsidiary establishment.

  • Global licensing negotiation advisory (KOTRA·KHIDI collaboration)
  • Up to KRW 300 million for FDA·EMA approval consulting
  • Subsidized residency at Boston and San Diego global hubs
  • 3. Use-Case Scenarios for SME Bio Companies

    AI Joint R&D Matching Application Process

  • Preparation: Document AI capabilities and clinical data assets
  • Registration: Register company profile on the KHIDI matching platform
  • Pharma engagement: 1:1 meetings with interested pharmaceutical companies (4 government-hosted matching events per year)
  • Joint proposal drafting: Include technical validation and market analysis
  • Evaluation: 60% technical merit, 40% commercial viability
  • Integrated Application System: Key Tips

  • Document unification: Submit business registration, financials, and technical materials only once
  • Cross-evaluation safeguards: Pre-check for duplicate funding eligibility
  • Consulting essential: Pre-diagnose which ministry's program best fits your stage
  • Connecting to Commercialization Infrastructure

  • GMP facilities: Priority access to Osong and Daegu-Gyeongbuk Advanced Medical Complexes
  • Preclinical CRO: Korea Institute of Toxicology (KIT) vouchers up to KRW 50 million
  • Clinical CRO: Free consulting from KoNECT (National Clinical Trial Support Foundation)
  • 4. KITIM Consulting Services

    KITIM offers the following consulting to help pharma-bio ventures effectively leverage the 4UP Strategy.

  • 4UP Stage-Specific Program Matching: Diagnose your growth stage and recommend optimal programs
  • Business Plan & Tech Commercialization Strategy: Specialized templates for AI joint R&D and global expansion programs
  • Government R&D Project Planning Advisory: TRL-based R&D roadmap design and evaluation response strategies
  • Integrated Cross-Ministry Application Support: Streamlined materials for simultaneous MOHW·MSS submissions
  • With the 4UP Strategy launching in earnest in 2026, swift action will define competitiveness. Partner with KITIM's expert consultants to prepare your pharma-bio venture's next leap forward. Request a free corporate diagnosis to receive tailored 4UP program and matching strategy recommendations for your company.

    Pharma-Bio Venture4UP StrategyWhole-Lifecycle SupportK-BlockbusterMOHW-MSS Collaboration

    Related Posts

    Bio

    Biologics Approval Fees Rise From KRW 8.03M to 20.71M, Data-Submission Drugs About 6x — MFDS Fee Regulation Amendment Pre-Announced Nov 6, 2026 (Comments Due Nov 26 / Dec 16): Filing Timing, Budget Review and Fee-Reduction Checks for Pharma & Bio SMEs

    Under the fee amendment MFDS proposed on November 6, approval fees for new biologics would rise from KRW 8.03 million to KRW 20.71 million, and fees for data-submission drugs would go up about sixfold. This guide shows pharma and bio SMEs how to review their filing timing, budgets, fee-reduction eligibility and public comments.

    2026-11-09
    Management Consulting

    Factories With 20–49 Workers Will Need a Safety or Health Manager — Korea's First Tripartite Agreement on November 5 (About 30,000 Sites in 5 Industries Including Manufacturing, Decree Amendment in 2027, Target Start 2028), the Owner-Led Alternative and Government Payroll Support: A Preparation Guide for Small Manufacturers

    Under Korea's November 5 tripartite agreement, about 30,000 sites with 20–49 workers in manufacturing and four other industries are expected to need a qualified safety or health manager from 2028. This guide covers what is settled and what is still open, the owner-led alternative, a cost comparison, and a preparation checklist.

    2026-11-09
    Government Programs

    SMEs Can Now Enter the KRW 1,500 Trillion 'Mega Project' Supply Chain from the Design Stage — MSS Joins as a Lead Ministry, Large/Mid-Tier–SME Councils and Regional Councils Launch (Nov 6 Plan to Expand Planning-Stage Participation), and How SMEs Targeting Semiconductor, AI Data Center and Physical AI Supply Chains Should Prepare Validation, Certification and Mass-Production Qualification

    MSS has joined Korea's KRW 1,500 trillion mega projects as a lead ministry and plans to bring SMEs in from the planning stage. This guide covers how the central and regional councils will work and how to line up support programs against the validation, certification and mass-production barriers.

    2026-11-09
    Updated daily

    Let AI find government support programs in this field

    Complete a 3-minute company assessment and we will recommend programs that fit your company, each with a match score. It is free.

    Get AI-Matched Programs for Free

    Need Consulting?

    Our technology innovation consultants will propose the optimal solution for your company.